DK2382474T3 - Opløselig icam-1 som biomarkør til forudsigelse af terapeutisk respons - Google Patents

Opløselig icam-1 som biomarkør til forudsigelse af terapeutisk respons Download PDF

Info

Publication number
DK2382474T3
DK2382474T3 DK10704115T DK10704115T DK2382474T3 DK 2382474 T3 DK2382474 T3 DK 2382474T3 DK 10704115 T DK10704115 T DK 10704115T DK 10704115 T DK10704115 T DK 10704115T DK 2382474 T3 DK2382474 T3 DK 2382474T3
Authority
DK
Denmark
Prior art keywords
sicam
vector
patient
immunogenic composition
recombinant
Prior art date
Application number
DK10704115T
Other languages
English (en)
Inventor
Bruce Acres
Bérangère Marie-Bastien
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK2382474T3 publication Critical patent/DK2382474T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Claims (16)

1. Ex-vivo-fremgangsmåde til at teste hvorvidt en patient vil respondere terapeutisk på en behandlingsfremgangsmåde omfattende administration af en immunogen sammensætning, hvor testfremgangsmåden omfatter trinnet at måle niveauer af sICAM-1 i en blodprøve taget fra patienten før administration af den immunogene sammensætning hvor lave niveauer af sICAM-1 indikerer at patienten vil udvikle et profylaktisk eller terapeutisk respons mod den immunogene sammensætning hvor lave niveauer af sICAM-1 værende mindre end 300 ng/ml, og hvor den immunogene sammensætning indeholder alt eller del af mindst et mål-antigen eller mindst en rekombinant vektor der udtrykker in vivo alt eller del af mindst en heterolog nukleotidsekvens der koder for alt eller del af mindst et målantigen.
2. Fremgangsmåden ifølge krav 1, hvor de lave niveauer af sICAM-1 betyder niveauer på mindre end 250 ng/ml.
3. Fremgangsmåden ifølge krav 1, hvor de lave niveauer af sICAM-1 betyder niveauer på mindre end 224 ng/ml.
4. Fremgangsmåden ifølge krav 1, hvor de lave niveauer af sICAM-1 betyder niveauer på mindre end 200 ng/ml.
5. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 4, hvor behandlingsfremgangsmåden er en fremgangsmåde til behandling af cancer.
6. Fremgangsmåden ifølge et hvilket som helst af de foregående krav, hvor niveauet af sICAM-1 måles med multi-analyt-plasmaprotein-profil eller enzym-bundet immunosorbent-assays.
7. Fremgangsmåden ifølge et hvilket som helst af de foregående krav, hvor niveauet af sICAM-1 bestemmes under anvendelse af antistoffer.
8. Fremgangsmåden ifølge et hvilket som helst af de foregående krav, hvor blodprøven vælges fra gruppen bestående af total blodprøve, plasma eller serum.
9. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 8, hvor den rekombinante vektor er en virusvektor.
10. Fremgangsmåden ifølge krav 9, hvor virusvektoren er replikations-kompetent.
11. Fremgangsmåden ifølge krav 9, hvor virusvektoren er replikations-defekt.
12. Fremgangsmåden ifølge et hvilket som helst af kravene 9 to 11, hvor den rekombinante vektor er en rekombinant adenovirusvektor.
13. Fremgangsmåden ifølge et hvilket som helst af kravene 9 to 11, hvor den rekombinante vektor er en rekombinant vaccinia-vektor.
14. Fremgangsmåden ifølge krav 13, hvor den rekombinante vaccinia-vektor er en rekombinant MVA-vektor.
15. Fremgangsmåden ifølge et hvilket som helst af de foregående krav, hvor patienten er en patient behandlet med et kemoterapeutisk middel.
16. Anvendelse af niveauer af sICAM-1 i en blodprøve som en biomarkør til forudsigelse af hvorvidt en patient er eller ikke mistænkt for at udvikle et profylaktisk eller terapeutisk immunrespons ved administration af en immunogen sammensætning, hvor blodprøven er taget fra patienten før administration af den immunogene sammensætning og hvor den immunogene sammensætning indeholder alt eller del af mindst et mål-antigen eller mindst en rekombinant vektor der udtrykker in vivo alt eller del af mindst en heterolog nukleotidsekvens der koder for alt eller del af mindst et mål-antigen.
DK10704115T 2009-01-20 2010-01-18 Opløselig icam-1 som biomarkør til forudsigelse af terapeutisk respons DK2382474T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305044 2009-01-20
EP09305294 2009-04-07
PCT/EP2010/050532 WO2010084100A1 (en) 2009-01-20 2010-01-18 Soluble icam-1 as biomarker for prediction of therapeutic response

Publications (1)

Publication Number Publication Date
DK2382474T3 true DK2382474T3 (da) 2015-04-07

Family

ID=42028081

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10704115T DK2382474T3 (da) 2009-01-20 2010-01-18 Opløselig icam-1 som biomarkør til forudsigelse af terapeutisk respons

Country Status (24)

Country Link
US (2) US20110312525A1 (da)
EP (1) EP2382474B1 (da)
JP (1) JP5379243B2 (da)
KR (1) KR20110116016A (da)
CN (1) CN102292638B (da)
AU (1) AU2010206195B2 (da)
BR (1) BRPI1006901A2 (da)
CA (1) CA2749192A1 (da)
CO (1) CO6390020A2 (da)
CR (1) CR20110438A (da)
DK (1) DK2382474T3 (da)
ES (1) ES2536747T3 (da)
HK (1) HK1161643A1 (da)
HR (1) HRP20150470T1 (da)
HU (1) HUE025015T2 (da)
IL (1) IL213098A (da)
MX (1) MX2011007386A (da)
NZ (1) NZ593749A (da)
PL (1) PL2382474T3 (da)
PT (1) PT2382474E (da)
SG (2) SG196837A1 (da)
TW (1) TWI440854B (da)
WO (1) WO2010084100A1 (da)
ZA (1) ZA201105271B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103175959B (zh) * 2013-02-28 2015-10-14 成都创宜生物科技有限公司 一种检测胎膜早破免疫层析试纸的制备方法
CN103235134B (zh) * 2013-05-08 2015-10-14 成都创宜生物科技有限公司 一种检测胎膜早破的免疫层析试纸及其制备方法
CN103698537A (zh) * 2014-01-06 2014-04-02 天津医科大学总医院 定量检测人血清可溶性细胞间粘附分子-1的化学发光免疫分析试剂盒及检测方法
WO2019173462A1 (en) * 2018-03-06 2019-09-12 Pepvax, Inc. Nucleic acid molecules and methods of using the same

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2602790B1 (fr) * 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
ES2080044T3 (es) 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular y sus ligandos de fijacion.
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
CA2008368C (en) 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
ATE247163T1 (de) 1991-03-07 2003-08-15 Virogenetics Corp Gentechnologisch hergestellter stamm für impfstoffe
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
ES2320315T5 (es) 1994-07-15 2012-12-05 University Of Iowa Research Foundation Oligonucleótidos inmunoestimuladores
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU731860B2 (en) 1996-07-25 2001-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU727308B2 (en) 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
DE60010654T2 (de) 1999-02-04 2005-06-16 Geron Corp., Menlo Park Replikativer virus gesteuert von dem promotor der reversen telomerase transkriptase zur behandlung von krebs
AU774437B2 (en) 1999-02-22 2004-06-24 Transgene S.A. Method for obtaining a purified viral preparation
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ES2288488T3 (es) 1999-11-15 2008-01-16 Onyx Pharmaceuticals, Inc. Adenovirus oncoliticos.
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
DK1335987T4 (da) 2000-11-23 2016-09-19 Bavarian Nordic As Modificeret variant af vaccinia virus ankara
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
US7381536B2 (en) 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient

Also Published As

Publication number Publication date
RU2011134415A (ru) 2013-02-27
US20140023686A1 (en) 2014-01-23
MX2011007386A (es) 2011-08-03
JP2012515893A (ja) 2012-07-12
AU2010206195A1 (en) 2010-07-29
IL213098A0 (en) 2011-07-31
CO6390020A2 (es) 2012-02-29
SG196837A1 (en) 2014-02-13
EP2382474A1 (en) 2011-11-02
NZ593749A (en) 2012-05-25
BRPI1006901A2 (pt) 2016-02-16
US20110312525A1 (en) 2011-12-22
ES2536747T3 (es) 2015-05-28
PT2382474E (pt) 2015-06-03
JP5379243B2 (ja) 2013-12-25
CN102292638B (zh) 2014-05-28
ZA201105271B (en) 2012-03-28
PL2382474T3 (pl) 2015-08-31
HK1161643A1 (en) 2012-07-27
HRP20150470T1 (hr) 2015-06-05
SG173065A1 (en) 2011-08-29
EP2382474B1 (en) 2015-03-04
AU2010206195B2 (en) 2016-03-10
CN102292638A (zh) 2011-12-21
HUE025015T2 (en) 2016-04-28
WO2010084100A1 (en) 2010-07-29
CA2749192A1 (en) 2010-07-29
CR20110438A (es) 2011-12-28
IL213098A (en) 2015-08-31
KR20110116016A (ko) 2011-10-24
TWI440854B (zh) 2014-06-11
TW201031917A (en) 2010-09-01

Similar Documents

Publication Publication Date Title
JP5650212B2 (ja) 患者を選択するためのバイオマーカーおよび関連方法
US20140023686A1 (en) Soluble icam-1 as biomarker for prediction of therapeutic response
US20140141039A1 (en) Biomarker for Monitoring Patients
US9207231B2 (en) Biomarker for selecting patients and related methods
RU2574984C2 (ru) Растворимый icam-1 в качестве биомаркера для прогнозирования терапевтического ответа
KR20110138354A (ko) 환자를 모니터링하기 위한 바이오마커